旨在优化老年2型糖尿病患者降糖药物的减药方案:OMED2研究随机对照试验方案
本研究为在荷兰86家全科诊所开展的1:1整群随机对照试验,旨在评估减药方案(DPP)对≥70岁过度治疗的2型糖尿病患者2型糖尿病并发症的影响。DPP包括对全科医生和执业护士的教育课程及支持计划,对照组接受常规照护,目标纳入406例患者,随访2年,主要结局为电子病历中记录的与治疗不足和过度治疗相关的2型糖尿病事件的累积发生率。
要点
- 老年2型糖尿病患者使用磺脲类或胰岛素时低血糖风险增加,荷兰已有减少降糖药物的指南。
- 本研究为在荷兰86家全科诊所开展的1:1整群随机对照试验,目标纳入406例患者,随访2年。
- DPP包括教育课程和支持计划,对照组接受常规照护,主要结局为与治疗不足和过度治疗相关的2型糖尿病事件的累积发生率。
核心结论
- 本研究将提供关于在基层医疗中针对过度治疗的老年2型糖尿病患者实施磺脲类/胰岛素减药方案的安全性和可行性的见解。
研究设计与样本
- 在荷兰86家全科诊所开展1:1整群随机对照试验,目标纳入406例患者,随访2年。
- DPP包括针对全科医生和执业护士的教育课程(主题包括减药必要性、启动减药的工具、与患者讨论减药的策略即共享决策)以及包含诊所访问的支持计划。
- 研究采用选择工具从全科医生电子病历中识别可能过度治疗的老年患者;入组资格基于荷兰指南所示的HbA1c目标,该目标取决于年龄、糖尿病病程、衰弱存在与否和预期寿命。
- 对照组提供常规照护。
- 主要结局通过计数电子病历中记录的与治疗不足和过度治疗相关的2型糖尿病事件的累积发生率来评估DPP对2型糖尿病并发症的影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Older patients with type 2 diabetes mellitus (T2D) have an increased risk of hypoglycaemic episodes when using sulphonylureas or insulin. In the Netherlands, guidelines exist for reducing glucose-lowering medication in older patients. However, evidence is lacking that a medication reduction in older patients can be safely pursued. Here, we will examine if promoting the deprescribing of insulin/sulphonylureas with a deprescribing programme (DPP) in general practice affects T2D-complications in older overtreated patients. METHODS: We will perform a 1:1 cluster randomised controlled trial in 86 general practices in the Netherlands. The DPP will consist of education sessions with general practitioners and practice nurses about reducing glucose-lowering medication in older patients (≥ 70 years). Topics of the sessions include the necessity of deprescribing, tools to initiate deprescribing and strategies to discuss deprescribing with patients (shared decision making). The DPP further includes a support programme with practice visits. The study will employ a selection tool to identify possibly overtreated older patients from the electronic medical records of the general practitioner. Eligibility for enrolment in the study will be based on HbA1c targets indicated by the Dutch guidelines, which depend on age, diabetes duration, presence of frailty, and life expectancy. The control group will provide usual care. We aim to include 406 patients. The follow-up period will be 2 years. For the primary outcome, the effect of the DPP on T2D-complications will be assessed by counting the cumulative incidence of events related to under- and overtreatment in T2D as registered in the electronic medical records. We shall perform an intention-to-treat analysis and an analysis including only patients for whom deprescribing was initiated. The implementation of the DPP in general practice will be evaluated quantitatively and qualitatively using the Extended Normalisation Process Theory (ENPT) and the Reach, Efficacy - Adoption, Implementation and Maintenance (RE-AIM) model. Other secondary outcomes include quality of life, cognitive functioning, events related to overtreatment or undertreatment, biomarkers of health, amount of blood glucose-lowering medication prescriptions, and cost-effectiveness. DISCUSSION: This study will provide insight into the safety and feasibility of a programme aimed at deprescribing sulphonylureas/insulin in older people with T2D who are treated in general practice. TRIAL REGISTRATION: ISRCTN Registry, ISRCTN50008265 , registered 09 March, 2023.
引用
- Andriessen C, Blom MT, van Hoek BACE, et al. A deprescribing programme aimed to optimise blood glucose-lowering medication in older people with type 2 diabetes mellitus, the OMED2-study: the study protocol for a randomised controlled trial. Trials. 2024. PMID: 39049109. doi:10.1186/s13063-024-08249-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。